
Imaging Biometricsâ Bold 2026 Pivot: Dropping Phase 2 Gallium Maltolate Plans to Accelerate Imaging Software Growth
Imaging Biometrics refocuses in 2026: why the company is stepping back from its cancer drug program to double down on imagingImaging Biometrics Ltd (L...














































